IPDA for High-Priority HIV-1 Subtypes to Enable Global Eradication Trials

基于序列的分析方法用于量化可复制的HIV储备库：尽管进行了有效的抗逆转录病毒治疗(ART)，但HIV-1在所有感染者中仍以前病毒DNA的形式存在于长期记忆的CD4T细胞中。这种具有复制能力的艾滋病毒宿主构成了治愈艾滋病毒感染的主要障碍。该计划的总体目标是开发和商业化用于临床艾滋病毒治愈干预的基于序列的艾滋病毒储存分析。具体地说，在临床研究中，如果成功，该检测应被设计为一种分析工具，用于监测具有复制能力的艾滋病毒储存库的大小，如果成功，则在预期的临床试验中监测。

Sequence-based Assays to Quantify the Replication-Competent HIV Reservoir: Despite effective antiretroviral therapy (ART), HIV-1 persists in all infected individuals as proviral DNA within long-lived memory CD4+ T cells. This replication-competent HIV reservoir constitutes the primary barrier for curing HIV infection. The overall goal of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. Specifically, the assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and if successful, in prospective clinical trials.